kr666.00
0.30% today
Stockholm, Oct 15, 05:29 pm CET
ISIN
SE0007692850
Symbol
CAMX

Camurus Stock price

kr666.00
-23.00 3.34% 1M
+96.00 16.84% 6M
+100.50 17.77% YTD
+12.00 1.83% 1Y
+415.00 165.34% 3Y
+484.00 265.93% 5Y
+600.00 909.09% 10Y
+600.00 909.09% 20Y
Stockholm, Closing price Wed, Oct 15 2025
-2.00 0.30%
ISIN
SE0007692850
Symbol
CAMX
Industry

Key metrics

Basic
Market capitalization
kr41.7b
Enterprise Value
kr38.4b
Net debt
positive
Cash
kr3.3b
Shares outstanding
59.7m
Valuation (TTM | estimate)
P/E
55.7 | 45.7
P/S
18.4 | 15.1
EV/Sales
17.0 | 13.9
EV/FCF
62.0
P/B
10.8
Financial Health
Equity Ratio
87.6%
Return on Equity
13.0%
ROCE
21.2%
ROIC
74.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr2.3b | kr2.8b
EBITDA
kr858.0m | kr1.1b
EBIT
kr838.8m | kr1.1b
Net Income
kr718.4m | kr871.4m
Free Cash Flow
kr619.8m
Growth (TTM | estimate)
Revenue
42.3% | 48.0%
EBITDA
241.0% | 128.5%
EBIT
254.3% | 138.2%
Net Income
221.8% | 103.4%
Free Cash Flow
-3.7%
Margin (TTM | estimate)
Gross
93.5%
EBITDA
37.9% | 40.2%
EBIT
37.0%
Net
31.7% | 31.5%
Free Cash Flow
27.3%
More
EPS
kr12.0
FCF per Share
kr10.4
Short interest
-
Employees
256
Rev per Employee
kr7.3m
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Camurus forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Camurus forecast:

Buy
83%
Hold
17%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,267 2,267
42% 42%
100%
- Direct Costs 147 147
16% 16%
6%
2,119 2,119
45% 45%
94%
- Selling and Administrative Expenses 662 662
33% 33%
29%
- Research and Development Expense 613 613
16% 16%
27%
858 858
241% 241%
38%
- Depreciation and Amortization 19 19
29% 29%
1%
EBIT (Operating Income) EBIT 839 839
254% 254%
37%
Net Profit 718 718
222% 222%
32%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 256
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today